Dynamics of Immune Checkpoints, Immune System, and BCG in the Treatment of Superficial Bladder Cancer
This paper aims to study the dynamics of immune suppressors/checkpoints, immune system, and BCG in the treatment of superficial bladder cancer. Programmed cell death protein-1 (PD-1), cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), and transforming growth factor-beta (TGF-β) are some of the exa...
Main Authors: | Farouk Tijjani Saad, Evren Hincal, Bilgen Kaymakamzade |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2017-01-01
|
Series: | Computational and Mathematical Methods in Medicine |
Online Access: | http://dx.doi.org/10.1155/2017/3573082 |
Similar Items
-
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
by: Antonio Lopez-Beltran, et al.
Published: (2021-01-01) -
Immune checkpoint blockade therapy for bladder cancer treatment
by: Jayoung Kim
Published: (2016-06-01) -
Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer
by: S. Lukacs, et al.
Published: (2013-01-01) -
Autophagy controls BCG-induced trained immunity and the response to intravesical BCG therapy for bladder cancer.
by: Kathrin Buffen, et al.
Published: (2014-10-01) -
EFFICACY OF SEQUENTIAL BCG AND MITOMYCIN VERSUS MITOMYCIN ALONE FOR TREATMENT OF SUPERFICIAL BLADDER CANCER
by: Hazim R Akal
Published: (2012-06-01)